01/24/23 8:30 AMNasdaq : APGN Apexigen Announces Approximately $2.8 Million Private Placement FinancingApexigen, Inc. (Nasdaq: APGN), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that it has entered into definitive agreementsRHEA-AIneutral
01/19/23 8:00 AMNasdaq : APGN clinical trialApexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023RHEA-AIvery positive
11/15/22 8:00 AMNasdaq : APGN earningsApexigen Reports Third Quarter 2022 Financial Results and Provides Business Update-Ongoing Phase 2 trial in collaboration with Columbia University demonstrated that sotigalimab (sotiga) in combination with doxorubicin achieved a median progression-free survival (mPFS) of 12.45 months in patients with liposarcoma (LPS)- -Encouraging mPFS data supports expansion of the LPS cohortRHEA-AIpositive
11/14/22 7:00 AMNasdaq : APGN clinical trialApexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma-Patients with liposarcoma (LPS) demonstrated prolonged median PFS (mPFS) relative to historical controls treated with standard of care of doxorubicin- -Encouraging PFS data from the ongoing investigator sponsored trial in collaboration with Columbia University supports expansion of the LPS cohortRHEA-AIvery positive
11/11/22 8:00 AMNasdaq : APGN clinical trialApexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting- The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved clinical response rate relative to the standard of care, pembrolizumab monotherapy- -Activation of antigen-presenting cells stimulated broad innate and adaptive anti-tumorRHEA-AIpositive
09/10/22 8:00 AMNasdaq : APGN clinical trialApexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022Apexigen, Inc. (NASDAQ: APGN)RHEA-AIpositive
09/07/22 8:01 AMNasdaq : APGN conferencesApexigen to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceApexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Company’s Management will participateRHEA-AIneutral
09/05/22 8:00 AMNasdaq : APGN clinical trialApexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022 Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2RHEA-AIneutral
08/04/22 8:00 AMNasdaq : APGN conferencesApexigen to Participate in the 2022 Wedbush PacGrow Healthcare ConferenceApexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that the Company’s Management will participateRHEA-AIneutral
08/01/22 8:00 AMNasdaq : APGN Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company-Common stock of Apexigen to commence trading on the Nasdaq Capital Market today under the ticker symbol “APGN”- -Clinical pipeline includes multiple Phase 2 studies of sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential- -Gross proceeds from the transaction totaledRHEA-AIpositive